KENNA RASIKLAL

“The new fees going into effect in July 2022 will only increase fees by about 3% across the board.”

Kenna Rasiklal
Principal Consultant
Asia Actual Singapore

Come grow with us in the US in Thailand in China in Korea in the Philippines in Taiwan in Hong Kong

Sources and Links

Sign Up For Our Newsletter to Stay Informed

Sign Up

The Health Science Authority to Raise Review Fees in Singapore in July 2022

Published on: January 20th, 2022

Singapore’s Health Science Authority (HSA) has announced that they will increase their review fees in Singapore for all registration routes in July 2022. The increased government fees are equivalent to about a 3% increase across the board. For a complete list, please visit the HSA’s official revised schedule of fees. Singapore remains a beacon of regulatory efficiency and market entrance for international medical device manufacturers selling in Asia. With a high standard of living and several leading hospitals in the region, Singapore is an important market for all manufacturer serious about establishing their brand in Asia.

Current fees can be found here and more information on the regulatory process can be found here.

New HSA Government Review Fees in Singapore

The HSA has announced that they will be increasing fees across the board in July 2022. While most fees have increased by about 3%, some of the updated fees can be found below.

Fees Class B Class B (New) Class C Class C (New) Class D Class D (New) Class D with a registrable drug Class D with a registrable drug (New)
Application fee $515 $530 $515 $530 $515 $530 $515 $530
Immediate route fee $925 $950 $3,090 $3,180 N.A. N.A. N.A. N.A.
Expedited route fee N.A. N.A. $3,090 $3,180 $5,560 $5,730 N.A. N.A.
Abridged route fee $1,850 $1,910 $3,605 $3,710 $5,870 $6,050 $10,200 $10,300
Full route fee $3,605 $3,710 $5,870 $6,050 $11,600 $11,800 $75,200 $75,400

All fees are in Singapore dollars. S$1,000 = US$705 as of January 2022

New Change Notification Review Fees in Singapore

The Health Science Authority has also updated the change notification review fees in Singapore by about 3%.

The updated change notification fees are as follows:

Notification Changes  Class B (Old) Class B (New) Class C (Old) Class C (New) Class D (Old) Class D (New)
Administrative $515 $530 $515 $530 $515 $530
Review $515 $530 N.A. N.A. N.A. N.A.
Technical N.A. N.A. $1,750 $1,800 $2,880 $2,970

All fees are in Singapore dollars. S$100 = US$70.5 as of January 2022

New Retention Fees in Singapore

Singapore’s Health Science Authority requires license holder pay an annual retention fees to maintain the SMDR listing and has also slightly increased these fees.

Classification 2021 Fees New Fees

(beginning July 1, 2022)
Class B $36 $37
Class C $62 $64
Class D $124 $128
Class D with registrable drug $124 $128

All fees are in Singapore dollars. S$100 = US$70.5 as of January 2022

Grow with Us

Asia Actual specializes in helping medical device manufacturers grow their sales in Asia with experienced, bi-lingual commercial and regulatory experts on the ground in Singapore. Contact Asia Actual today if you have questions or need support importing medical products into Singapore.

Blog Posts

CDSCO Issues Updates to IVD Classification List in India

The Central Drugs Standard Control Organisation (CDSCO) of India issued a notice (PDF) on October 25, 2023 classifying in-vitro diagnostic (IVD) medical devices under medical device rules. The updates to IVD classification in India include intended use, associated risk, and other parameters.
Read more

Embracing Innovation and Collaboration: Highlights from the 15th CII Global MedTech Summit

On October 6, 2023, a team of enthusiastic members from the AAI (Artificial Intelligence and Innovation) group, including Ashoniya Puri, Sanjay Singh, and Rajat Budhori, had the honor of attending the prestigious 15th CII Global MedTech Summit. Hosted by the Confederation of Indian Industry (CII), one of India's largest industry bodies, this event brought together key players in the MedTech sector, both from India and abroad. The summit revolved around the central theme, "Paving the way for a USD 50 billion MedTech Industry by 2030," signifying a collective vision for the industry's future growth.
Read more

Bangladesh LAUNCHES NEW MEDICAL DEVICE REGULATIONS

On September 18, 2023, The Directorate General of Drug Administration (DGDA) published the Drug and Cosmetics Act 2023 formalizing the regulatory requirements of medical and diagnostic devices in Bangladesh with immediate effect.  A translated version of the document is available on Asia Actual’s website here.  All medical devices now require a Marketing Authorization Certificate to clear Customs and be sold on the market in Bangladesh.
Read more